Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Planned secondary offering of 2.5 mil. shares is withdrawn by the company March 19. Adverse market conditions are cited. The Gaithersburg, Maryland-based manufacturer of DNA tests for human papillomavirus notes that despite the move, "the company has a strong balance sheet and the financial resources to continue the execution of its growth strategy." Cash on hand stood at approximately $6.6 mil. as of Dec. 31. Second-quarter (ended Dec. 31) revenues were up 48% to $7.8 mil. A net loss of $1.6 mil. for the quarter was roughly even with that of the comparable quarter last year. Digene expects to file a PMA supplement by year-end for a primary screening indication of its HybridCapture 2 HPV test (1"The Gray Sheet" Feb. 26, 2001, p. 15)

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts